

Kelvin CÃ©sar de Andrade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9408379/publications.pdf>

Version: 2024-02-01

17
papers

434
citations

840776

11
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

852
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein particle alterations due to androgen therapy in individuals with dyskeratosis congenita. EBioMedicine, 2022, 75, 103760.	6.1	1
2	Spectrum and Incidence of Skin Cancer among Individuals with Li-Fraumeni Syndrome. Journal of Investigative Dermatology, 2022, 142, 2534-2537.e1.	0.7	1
3	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death and Differentiation, 2022, 29, 1071-1073.	11.2	53
4	Fundamental immuneâ€œoncogenicity trade-offs define driver mutationâ€™fitness. Nature, 2022, 606, 172-179.	27.8	23
5	Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma. Cellular and Molecular Neurobiology, 2021, 41, 1285-1297.	3.3	5
6	Specifications of the ACMG/AMP variant interpretation guidelines for germline <i>TP53</i> variants. Human Mutation, 2021, 42, 223-236.	2.5	81
7	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. JNCI Cancer Spectrum, 2021, 5, pkab007.	2.9	11
8	Pathogenic germline <i>IKZF1</i> variant alters hematopoietic gene expression profiles. Journal of Physical Education and Sports Management, 2021, 7, a006015.	1.2	5
9	Cancer incidence, patterns, and genotypeâ€œphenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncology, The, 2021, 22, 1787-1798.	10.7	29
10	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	10.3	37
11	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. American Journal of Human Genetics, 2020, 106, 264-271.	6.2	25
12	Response to: Concern regarding classification of germline TP53 variants as likely pathogenic. Human Mutation, 2019, 40, 832-833.	2.5	1
13	Variable population prevalence estimates of germline <i>TP53</i> variants: A gnomAD-based analysis. Human Mutation, 2019, 40, 97-105.	2.5	66
14	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. Genome Medicine, 2018, 10, 99.	8.2	15
15	Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients. Cancer Imaging, 2018, 18, 27.	2.8	19
16	Frequency of Thyroid Carcinoma in Brazilian <i>TP53</i> p.R337H Carriers With Li Fraumeni Syndrome. JAMA Oncology, 2017, 3, 1400.	7.1	21
17	Higher-than-expected population prevalence of potentially pathogenic germline<i>TP53</i> variants in individuals unselected for cancer history. Human Mutation, 2017, 38, 1723-1730.	2.5	40